Abstract:T cell immunoreceptor with immunoglobulin and ITIM domain (TIGIT), an immune checkpoint, plays a pivotal role in immune suppression. However its role in tumor immunity and correlation with the genetic and epigenetic alterations remains unknown. Here, we comprehensively analyzed the expression patterns of the TIGIT and its value of prognostic prediction among 33 types of cancers based on the data collected from The Cancer Genome Atlas (TCGA) and the Genotype-Tissue Expression projects (GTEx). Furthermore, the correlations of TIGIT with pathological stages, tumor-infiltrating immune cells (TIICs), signatures of T cells subtypes, immune checkpoint genes, the degree of Estimation of STromal and Immune cells in MAlignant Tumor tissues using the Expression data (ESTIMATE), tumor mutation burden (TMB), microsatellite instability (MSI), mismatch repair (MMR) genes, and DNA methyltransferases (DNMTs) were also explored. Gene functional enrichment was conducted by Gene Set Enrichment Analysis (GSEA). Our results showed that the expression of TIGIT was upregulated in most of the cancer types. Cox regression model showed that high expression of TIGIT in tumor samples correlates with poor prognosis in KIRC, KIRP, LGG, UVM, and with favorable prognosis in BRCA, CECS, HNSC, SKCM. TIGIT expression positively correlated with advanced stages, TIICs, the signatures of effector T cells, exhausted T cells, effector Tregs and the degree of ESTIMATE in KIRC, KIRP and UVM. TIGIT expression also positively correlated with CTLA4, PDCD1 (PD-1), CD274 (PD-L1), ICOS in most of the cancer types. Furthermore, the expression of TIGIT was correlated with TMB, MSI, MMR genes and DNMTs in different types of cancers. GSEA analysis showed that the expression of TIGIT was related to cytokine-cytokine receptor interaction, allograft rejection, oxidative phosphorylation. These findings suggested that TIGIT could serve as a potential biomarker for prognosis and a novel target for immunotherapies in cancers.

T-cell Immunoglobulin and ITIM Domain in Cancer Immunotherapy: A Focus on Tumor-Infiltrating Regulatory T Cells.

Cancer Immunotherapies Targeting Tumor-Associated Regulatory T Cells

TIGIT: A promising target to overcome the barrier of immunotherapy in hematological malignancies.

TIGIT, A Novel Therapeutic Target for Tumor Immunotherapy

Targeting TIGIT for cancer immunotherapy: recent advances and future directions

Tumor Immune Checkpoints and Their Associated Inhibitors

TIGIT in cancer immunotherapy

TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer

TIGIT as an emerging immune checkpoint

Update in TIGIT Immune-Checkpoint Role in Cancer

T-cell immunoglobulin and ITIM domain, as a potential immune checkpoint target for immunotherapy of colorectal cancer

Target therapy of TIGIT; a novel approach of immunotherapy for the treatment of colorectal cancer

The Landscape of TIGIT Target and Clinical Application in Diseases

TIGIT signaling and its influence on T cell metabolism and immune cell function in the tumor microenvironment

TIGIT, a novel immune checkpoint therapy for melanoma

A pan-cancer analysis revealing the role of TIGIT in tumor microenvironment

TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy

A Pan-Cancer Analysis Revealing the Role 2 of TIGIT in Tumor Microenvironment

TIGIT as a Promising Therapeutic Target in Autoimmune Diseases

TIGIT Blockade Reshapes the Tumor Microenvironment Based on the Single-cell RNA-Sequencing Analysis

Intrinsic Expression of Immune Checkpoint Molecule TIGIT Could Help Tumor Growth in vivo by Suppressing the Function of NK and CD8+ T Cells